|
1
|
Sagara N and Katoh M: Mitomycin C
resistance induced by TCF-3 overexpression in gastric cancer cell
line MKN28 is associated with DT-diaphorase down-regulation. Cancer
Res. 60:5959–5962. 2000.PubMed/NCBI
|
|
2
|
Haimeur A, Conseil G, Deeley RG and Cole
SPC: The MRP-related and BCRP/ABCG2 multidrug resistance proteins:
biology, substrate specificity and regulation. Curr Drug Metab.
5:21–53. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Allikmets R, Schriml LM, Hutchinson A,
Romano-Spica V and Dean M: A human placenta-specific ATP-binding
cassette gene (ABCP) on chromosome 4q22 that is involved in
multidrug resistance. Cancer Res. 58:5337–5339. 1998.PubMed/NCBI
|
|
4
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyake K, Mickley L, Litman T, et al:
Molecular cloning of cDNAs which are highly overexpressed in
mitoxantrone-resistant cells: demonstration of homology to ABC
transport genes. Cancer Res. 59:8–13. 1999.
|
|
6
|
Ewart GD and Howells AJ: ABC transporters
involved in transport of eye pigment precursors in
Drosophilamelanogaster. Methods Enzymol. 292:213–224. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brangi M, Litman T, Ciotti M, et al:
Camptothecin resistance: role of the ATP-binding cassette (ABC),
mitoxantrone-resistance half-transporter (MXR), and potential for
glucuronidation in MXR-expressing cells. Cancer Res. 59:5938–5946.
1999.PubMed/NCBI
|
|
8
|
Litman T, Brangi M, Hudson E, et al: The
multidrug-resistant phenotype associated with overexpression of the
new ABC half-transporter, MXR (ABCG2). J Cell Sci. 113:2011–2021.
2000.PubMed/NCBI
|
|
9
|
Maliepaard M, Scheffer GL, Faneyte IF, et
al: Subcellular localization and distribution of the breast cancer
resistance protein transporter in normal human tissues. Cancer Res.
61:3458–3464. 2001.PubMed/NCBI
|
|
10
|
Yang CH, Schneider E, Kuo ML, Volk EL,
Rocchi E and Chen YC: BCRP/MXR/ABCP expression in
topotecan-resistant human breast carcinoma cells. Biochem
Pharmacol. 60:831–837. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kawabata S, Oka M, Shiozawa K, et al:
Breast cancer resistance protein directly confers SN-38 resistance
of lung cancer cells. Biochem Biophys Res Commun. 280:1216–1223.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen YN, Mickley LA, Schwartz AM, Acton
EM, Hwang JL and Fojo AT: Characterization of adriamycin-resistant
human breast cancer cells which display overexpression of a novel
resistance-related membrane protein. J Biol Chem. 265:10073–10080.
1990.
|
|
13
|
Volk EL, Rohde K, Rhee M, McGuire JJ,
Doyle LA, Ross DD and Schneider E: Methotrexate cross-resistance in
a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell
line is attributable to enhanced energy-dependent drug efflux.
Cancer Res. 60:3514–3521. 2000.
|
|
14
|
Volk EL, Farley KM, Wu Y, Li F, Robey RW
and Schneider E: Overexpression of wild-type breast cancer
resistance protein mediates methotrexate resistance. Cancer Res.
62:5035–5040. 2002.PubMed/NCBI
|
|
15
|
Ifergan I, Shafran A, Jansen G, Hooijberg
JH, Scheffer GL and Assaraf YG: Folate deprivation results in the
loss of breast cancer resistance protein (BCRP/ABCG2) expression. A
role for BCRP in cellular folate homeostasis. J Biol Chem.
279:25527–25534. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shafran A, Ifergan I, Bram E, et al: ABCG2
harboring the Gly482 mutation confers high-level resistance to
various hydrophilic antifolates. Cancer Res. 65:8414–8422. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Houghton PJ, Germain GS, Harwood FC,
Schuetz JD, Stewart CF, Buchdunger E and Traxler P: Imatinib
mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and
reverses resistance to topotecan and SN-38 in vitro. Cancer Res.
64:2333–2337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Cusatis G, Brahmer J, et al:
Association of variant ABCG2 and the pharmacokinetics of epidermal
growth factor receptor tyrosine kinase inhibitors in cancer
patients. Cancer Biol Ther. 6:432–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brendel C, Scharenberg C, Dohse M, et al:
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity
interaction with ABCG2 on primitive hematopoietic stem cells.
Leukemia. 21:1267–1275. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Polgar O, Okada M, Esser L, Bates SE
and Xia D: Towards understanding the mechanism of action of the
multidrug resistance-linked half-ABC transporter ABCG2: a molecular
modeling study. J Mol Graph Model. 25:837–851. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fairbrother WG, Yeo GW, Yeh R, Goldstein
P, Mawson M, Sharp PA and Burge CB: RESCUE-ESE identifies candidate
exonic splicing enhancers in vertebrate exons. Nucleic Acids Res.
32:W187–W190. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fairbrother WG, Holste D, Burge CB and
Sharp PA: Single nucleotide polymorphism-based validation of exonic
splicing enhancers. PLoS Biol. 2:E2682004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cuff JA, Clamp ME, Siddiqui AS, Finlay M
and Barton GJ: JPred: a consensus secondary structure prediction
server. Bioinformatics. 14:892–893. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Finn RD, Mistry J, Schuster-Bockler B, et
al: Pfam: clans, web tools and services. Nucleic Acids Res.
34:D247–D251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Letunic I, Copley RR, Pils B, Pinkert S,
Schultz J and Bork P: SMART 5: domains in the context of genomes
and networks. Nucleic Acids Res. 34:D257–D260. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lambert C, Leonard N, De Bolle X and
Depiereux E: ESyPred3D: prediction of proteins 3D structures.
Bioinformatics. 18:1250–1256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
To KKW, Zhan Z and Bates SE: Aberrant
promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell
Biol. 26:8572–8585. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korenaga Y, Naito K, Okayama N, et al:
Association of the BCRP C421A polymorphism with nonpapillary renal
cell carcinoma. Int J Cancer. 117:431–434. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Honjo Y, Hrycyna CA, Yan QW, et al:
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate
specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res.
61:6635–6639. 2001.PubMed/NCBI
|
|
30
|
Ejendal KFK, Diop NK, Schweiger LC and
Hrycyna CA: The nature of amino acid 482 of human ABCG2 affects
substrate transport and ATP hydrolysis but not substrate binding.
Protein Sci. 15:1597–1607. 2006. View Article : Google Scholar : PubMed/NCBI
|
